Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

The Histone Methyltransferase KMT2D promotes Natural Killer cell effector molecule release.

Created on 01 Oct 2026

Authors

Katelynn R Kazane, Jeong Hyun Ji, Georgia R Lill, Sebastian Zolog, Christian G Bustillos, David Hsieh, Evelyn Hernandez-Almonte, Luis A Pedroza, Maureen A Su, Jordan S Orange, Timothy E O'Sullivan

Published in

bioRxiv : the preprint server for biology. Sep 22, 2026. Epub Sep 22, 2026.

Abstract

Natural Killer (NK) cells eliminate virally infected and cancerous cells by secreting cytotoxic granules and pro-inflammatory cytokines. However, the epigenetic mechanisms that coordinate these processes in human NK cells remain poorly understood. We identified two NK deficiency (NKD) patients with mutations in the histone methyltransferase KMT2D that demonstrated impaired cytotoxicity and degranulation. CRISPR-mediated KMT2D deletion or introduction of a patient-specific mutation in healthy human NK cells was sufficient to inhibit effector functions. NK cell-specific KMT2D deletion in mice resulted in defective NK cell degranulation and IFN-γ production, increasing mortality following MCMV infection. KMT2D loss reduced H3K4me1 deposition, associated with decreased levels of RAB3D. RAB3D-deficient human NK cells reduced the release of GZMB and IFN-γ, without impacting intracellular levels. Thus, KMT2D acts as a conserved epigenetic regulator of mature NK cell functions, promoting rapid effector molecule release.
Mutations in KMT2D are associated with human NKD.KMT2D is required for NK cell cytotoxicity and degranulation.Loss of KMT2D in mouse NK cells increases susceptibility to MCMV infection.KMT2D regulates RAB3D to enhance the release of effector molecules.

PMID:
42818056
Bibliographic data and abstract were imported from PubMed on 01 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement